Qishan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qishan Liu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Qian Yan
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China
10 shared publications Dawang Zhou
9 shared publications- Huichuan Yu
Guangdong Institute of Gastroenterology, Guangzhou, China
9 shared publications - Jinxin Lin
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
9 shared publications - Meijin Huang
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
9 shared publications - Peisi Li
Guangdong Institute of Gastroenterology, Guangzhou, China
9 shared publications
Latest Publications
- 18 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (876)
Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer
Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness–associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8 + T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti–PD-1 (programmed cell death protein–1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.
- 18 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (876)
Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer
Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness–associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8 + T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti–PD-1 (programmed cell death protein–1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 5. Effects of CLK1 modulation on YAP1 downstream target gene expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 5. Effects of CLK1 modulation on YAP1 downstream target gene expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 2. CLK1 plays a crucial role in facilitating in vivo tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 2. CLK1 plays a crucial role in facilitating in vivo tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 4. Spatial transcriptomic analysis of CLK1 expression and its correlation with immune markers.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 4. Spatial transcriptomic analysis of CLK1 expression and its correlation with immune markers.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Colorectal cancer is a highly heterogeneous malignancy characterized by complex interactions between tumor cells and the immune system. The tumor microenvironment (TME) plays a crucial role in colorectal cancer progression and response to therapy. However, the mechanisms regulating TME composition remain poorly understood because of the genetic and phenotypic diversity of tumor cells. In this study, we investigated the tumor-intrinsic factors contributing to TME formation and evaluated genotype-based combination strategies to enhance the efficacy of immunotherapy in colorectal cancer. Using RNA sequencing, single-cell analysis, and immunohistochemistry (IHC), we identified pro-oncogenic proteins associated with low immune activation. Functional studies using in vitro co-culture systems, subcutaneous colorectal tumor models, flow cytometry, and IHC revealed a role for CDC-like kinase 1 (CLK1) in tumor progression and immunosuppressive TME remodeling. Mechanistically, CLK1 activation led to hyperactivation of the Hippo signaling pathway, promoting nuclear translocation of Yes-associated protein (YAP) and subsequent transcriptional upregulation of the chemokine CXCL1. Elevated CLK1 expression correlated with increased infiltration of myeloid-derived suppressor cells (MDSC) and impaired antitumor immune responses. Knockdown (KD) of CLK1 significantly reduced MDSC recruitment and restored CD8+ T-cell activity. Moreover, combined CLK1 KD and anti–PD-1 therapy enhanced intratumoral CD8+ T-cell infiltration to a greater extent and elicited robust antitumor responses in murine colorectal cancer models. Collectively, our findings identify the CLK1–Hippo/YAP–CXCL1 signaling axis as a regulator of immune evasion and TME remodeling in colorectal cancer and highlight the potential of therapeutically targeting this axis to improve the efficacy of immune checkpoint blockade.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Colorectal cancer is a highly heterogeneous malignancy characterized by complex interactions between tumor cells and the immune system. The tumor microenvironment (TME) plays a crucial role in colorectal cancer progression and response to therapy. However, the mechanisms regulating TME composition remain poorly understood because of the genetic and phenotypic diversity of tumor cells. In this study, we investigated the tumor-intrinsic factors contributing to TME formation and evaluated genotype-based combination strategies to enhance the efficacy of immunotherapy in colorectal cancer. Using RNA sequencing, single-cell analysis, and immunohistochemistry (IHC), we identified pro-oncogenic proteins associated with low immune activation. Functional studies using in vitro co-culture systems, subcutaneous colorectal tumor models, flow cytometry, and IHC revealed a role for CDC-like kinase 1 (CLK1) in tumor progression and immunosuppressive TME remodeling. Mechanistically, CLK1 activation led to hyperactivation of the Hippo signaling pathway, promoting nuclear translocation of Yes-associated protein (YAP) and subsequent transcriptional upregulation of the chemokine CXCL1. Elevated CLK1 expression correlated with increased infiltration of myeloid-derived suppressor cells (MDSC) and impaired antitumor immune responses. Knockdown (KD) of CLK1 significantly reduced MDSC recruitment and restored CD8+ T-cell activity. Moreover, combined CLK1 KD and anti–PD-1 therapy enhanced intratumoral CD8+ T-cell infiltration to a greater extent and elicited robust antitumor responses in murine colorectal cancer models. Collectively, our findings identify the CLK1–Hippo/YAP–CXCL1 signaling axis as a regulator of immune evasion and TME remodeling in colorectal cancer and highlight the potential of therapeutically targeting this axis to improve the efficacy of immune checkpoint blockade.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Table S2. Information on the antibodies used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Table S2. Information on the antibodies used in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Table S1. Primers and shRNA sequences used in the study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Table S1. Primers and shRNA sequences used in the study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 3. CLK1 negatively regulates CD8+ T cell activity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 3. CLK1 negatively regulates CD8+ T cell activity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 1. CLK1 is associated with a decreased response to immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Supplementary Fig 1. CLK1 is associated with a decreased response to immunotherapy.
- Open Access
- 13 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (5) , 875-891
CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Colorectal cancer is a highly heterogeneous malignancy characterized by complex interactions between tumor cells and the immune system. The tumor microenvironment (TME) plays a crucial role in colorectal cancer progression and response to therapy. However, the mechanisms regulating TME composition remain poorly understood because of the genetic and phenotypic diversity of tumor cells. In this study, we investigated the tumor-intrinsic factors contributing to TME formation and evaluated genotype-based combination strategies to enhance the efficacy of immunotherapy in colorectal cancer. Using RNA sequencing, single-cell analysis, and immunohistochemistry (IHC), we identified pro-oncogenic proteins associated with low immune activation. Functional studies using in vitro co-culture systems, subcutaneous colorectal tumor models, flow cytometry, and IHC revealed a role for CDC-like kinase 1 (CLK1) in tumor progression and immunosuppressive TME remodeling. Mechanistically, CLK1 activation led to hyperactivation of the Hippo signaling pathway, promoting nuclear translocation of Yes-associated protein (YAP) and subsequent transcriptional upregulation of the chemokine CXCL1. Elevated CLK1 expression correlated with increased infiltration of myeloid-derived suppressor cells (MDSC) and impaired antitumor immune responses. Knockdown (KD) of CLK1 significantly reduced MDSC recruitment and restored CD8+ T-cell activity. Moreover, combined CLK1 KD and anti–PD-1 therapy enhanced intratumoral CD8+ T-cell infiltration to a greater extent and elicited robust antitumor responses in murine colorectal cancer models. Collectively, our findings identify the CLK1–Hippo/YAP–CXCL1 signaling axis as a regulator of immune evasion and TME remodeling in colorectal cancer and highlight the potential of therapeutically targeting this axis to improve the efficacy of immune checkpoint blockade.
- 13 February 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (5) , 875-891
Open AccessCLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer
Colorectal cancer is a highly heterogeneous malignancy characterized by complex interactions between tumor cells and the immune system. The tumor microenvironment (TME) plays a crucial role in colorectal cancer progression and response to therapy. However, the mechanisms regulating TME composition remain poorly understood because of the genetic and phenotypic diversity of tumor cells. In this study, we investigated the tumor-intrinsic factors contributing to TME formation and evaluated genotype-based combination strategies to enhance the efficacy of immunotherapy in colorectal cancer. Using RNA sequencing, single-cell analysis, and immunohistochemistry (IHC), we identified pro-oncogenic proteins associated with low immune activation. Functional studies using in vitro co-culture systems, subcutaneous colorectal tumor models, flow cytometry, and IHC revealed a role for CDC-like kinase 1 (CLK1) in tumor progression and immunosuppressive TME remodeling. Mechanistically, CLK1 activation led to hyperactivation of the Hippo signaling pathway, promoting nuclear translocation of Yes-associated protein (YAP) and subsequent transcriptional upregulation of the chemokine CXCL1. Elevated CLK1 expression correlated with increased infiltration of myeloid-derived suppressor cells (MDSC) and impaired antitumor immune responses. Knockdown (KD) of CLK1 significantly reduced MDSC recruitment and restored CD8+ T-cell activity. Moreover, combined CLK1 KD and anti–PD-1 therapy enhanced intratumoral CD8+ T-cell infiltration to a greater extent and elicited robust antitumor responses in murine colorectal cancer models. Collectively, our findings identify the CLK1–Hippo/YAP–CXCL1 signaling axis as a regulator of immune evasion and TME remodeling in colorectal cancer and highlight the potential of therapeutically targeting this axis to improve the efficacy of immune checkpoint blockade.